logo
EU says it can't kick Russia out of flagship nuclear fusion project

EU says it can't kick Russia out of flagship nuclear fusion project

Euractiv25-07-2025
Moscow cannot be expelled from Europe's top nuclear fusion project, EU energy commissioner Dan Jørgensen has confirmed in response to concerns raised by members of the European Parliament.
The project, called the International Thermonuclear Experimental Reactor (ITER), is intended to prove that the Holy Grail of clean energy can be achieved: an emissions-free source based on the same reactions that power the stars.
ITER is an international collaboration based in the south of France, to which Europe contributes almost half of the costs, with the rest shared equally by China, India, Japan, the Republic of Korea, the Russian Federation and the United States.
Russia has faced international condemnation and growing isolation, as well as a raft of Western sanctions, since launching its unprovoked, full-scale invasion of Ukraine in February 2022. The EU has significantly reduced its energy dependency on Russia.
In May, three members of the centre-right European People's Party asked what the European Commission was planning to do to end Russia's participation in ITER, noting the recent plan to end the bloc's dependency on Russia for nuclear power (as well as fossil fuels) was 'silent on fusion energy".
Jørgensen replied today that the EU does not have the authority to force Russia out of the project.
"The ITER Agreement does not provide for the possibility of terminating the participation or suspension of the rights of any ITER Member, including the participation in the ITER Council – the governing body," the EU's most senior energy official wrote.
Acountry can leave only 'on its own accord," he said.
Russia, like the other international partners in the project, contributes 9.1% to the construction of the experimental fusion reactor. Consortium members' contributions are mainly 'in-kind', in the form of components and systems technology, with only 10% in cash.
'This unique procurement sharing program has an important purpose, allowing all members to gain direct industrial experience in key fusion technologies,' ITER's website reads.
Russia 'has fulfilled all its in-kind contributions', Jørgensen said in his statement. As a consequence, the dependency on Moscow was 'now reduced in this regard', he said, adding that 'bilateral contacts and engagement with Russia are minimised' and that the reactor's operations won't depend on Russian intellectual property rights.
(rh, aw)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sweden backs EU-wide patent reform to support drug innovation
Sweden backs EU-wide patent reform to support drug innovation

Euractiv

timean hour ago

  • Euractiv

Sweden backs EU-wide patent reform to support drug innovation

Hoping to support pharmaceutical innovation and competitiveness, Stockholm is advocating for a Unitary Patent System. Sweden is one of eleven EU Member States pushing the Danish Presidency to finalise an EU system for enhanced patent protection for medicines. Supplementary Protection Certificates (SPCs) have been in place for several decades in the European Union. They are an intellectual property right that grants a patentholder an additional five years of patent protection, primarily for medicine patents. So far, each Member State has to implement such protection nationally, resulting in varying outcomes between countries. However, a unitary system was proposed by the EU Commission in 2023. Under this proposal, a unitary SPC would be relevant in the 18 EU states that have currently joined the so-called Unitary Patent System. 'A unitary SPC would be an important piece of the puzzle to finalise the Unitary Patent System and a reform that would boost innovation and competitiveness', Louise Petrelius, a senior advisor at the Swedish Ministry of Justice, told Euractiv. She explains that the system is expected to streamline the extension of patent protection for both medicinal and plant protection products (e.g. pesticides) in the EU by introducing a single, unified procedure across participating member states. 'This aims to simplify the current system, which requires separate applications in each country, reducing costs and administrative burden for applicants.' Longer time to market According to Petrelius, SPCs aim to compensate patent holders for the extra time it takes to bring their products to market, due to the compulsory lengthy testing and clinical trials required prior to obtaining regulatory marketing approval. The protection for patents in the EU is 20 years. An SPC could extend such a patent right for a maximum of five years. As the SPC mechanism extends the market exclusivity of a patented medicine beyond the initial patent term, it could delay the entry of generic or biosimilar competition and maintain higher prices for a longer period in the EU. According to the Swedish Intellectual Property Office (PRV), companies producing generics and biosimilars are only allowed to start manufacturing and storing a medicine during the extra five-year protection period if their products are to be exported outside the EU. Civil society organisations, as Médecins Sans Frontières (MSF), have previously called upon the EU to abolish the SPC mechanism, saying it contributes 'to high drug prices and hinders access to essential medicines by delaying the availability of generic and biosimilar alternatives'. No price analysis Johan Pontén, International Coordinator at the Swedish Dental and Pharmaceutical Benefits Agency (TLV), told Euractiv that 'TLV agrees with the Swedish government that a centralised SPC system creates more uniform and simpler management within the EU, which is positive,' adding, however: 'We have not been tasked with analysing how a changed system could affect the prices of medicines and therefore cannot comment on it'. Meanwhile, according to the Swedish Ministry of Justice, there is no ongoing discussion in the EU that links higher prices to the SPC proposal. 'Since the question of the existence of SPCs is not subject to negotiation, it is not discussed in this project. In general, my view is that Sweden is in favour of a system that promotes innovation and attractiveness on the pharmaceutical side, where intellectual property protection is an important component,' Petter Söderbäck, also a senior legal advisor at the Swedish Ministry of Justice, told Euractiv. Euractiv has requested a comment from the Danish Presidency, but has not received a response so far. [Edited by Vasiliki Angouridi]

Trump and Putin will meet in the ‘coming days'
Trump and Putin will meet in the ‘coming days'

Euractiv

timean hour ago

  • Euractiv

Trump and Putin will meet in the ‘coming days'

Trump said Wednesday he was likely to meet Putin face-to-face "very soon." "At the suggestion of the American side, an agreement has been reached in principle to hold a bilateral summit in the coming days," Kremlin aide Yuri Ushakov was quoted as saying on Thursday by Russian state news agencies. "We are now starting to work out the details together with our American colleagues," Ushakov said. The Kremlin said a venue had been agreed "in principle", but did not indicate where the summit could take place. "Next week has been set as a target date," Ushakov added. Zelenskyy calls for meeting Russian bombardments have forced millions to flee their homes and destroyed swathes of eastern and southern Ukraine. Putin has resisted multiple calls from the United States, Europe and Kyiv for a ceasefire. At talks in Istanbul, Russian negotiators have outlined hardline territorial demands if Ukraine wants Russia to halt its advance – calling for Kyiv to withdraw from territory it still controls and renounce Western military support. Moscow has also repeatedly sought to cast doubt on Zelenskyy's legitimacy and ruled out a meeting between the two leaders until after the terms of a peace deal have been agreed. The announcement of the upcoming summit comes a day after US envoy Steve Witkoff met Putin in Moscow. Witkoff proposed a trilateral meeting with Ukrainian President Volodymyr Zelenskyy, but Russia did not respond to that proposal, Ushakov said. "The Russian side left this option completely without comment," he added. Zelenskyy earlier Thursday had refreshed his call for a meeting with Putin – which he says is the only way to make progress towards peace. "We in Ukraine have repeatedly said that finding real solutions can be truly effective at the level of leaders," Zelenskyy wrote on social media. "It is necessary to determine the timing for such a format and the range of issues to be addressed," he added. The Ukrainian leader said Thursday morning that he had planned to hold "several" conversations throughout the course of the day, including with German Chancellor Friedrich Merz, as well as French and Italian officials. "There will also be communication at the level of national security advisors," Zelenskyy added. "The main thing is for Russia, which started this war, to take real steps to end its aggression," Zelenskyy added. Trump wants end to Russia's war in Ukraine by 8 August, US tells UN Earlier this week, Trump said that he was reducing the 50-day deadline he gave Russia over its war in Ukraine to "10 or 12" days (vib)

EU stocks rise, euro strengthens as Trump's tariffs kick in
EU stocks rise, euro strengthens as Trump's tariffs kick in

Euractiv

timean hour ago

  • Euractiv

EU stocks rise, euro strengthens as Trump's tariffs kick in

The euro strengthened and European stocks surged in early trading on Thursday, as Trump's sweeping 'reciprocal' tariffs – including a blanket 15% levy on EU exports – entered into force. The STOXX Europe 600, a broad measure of European equities, was up 0.9% as of noon CEST. The DAX, a stock index comprising major German blue chip companies, rose by 1.9%, while the Paris-based CAC 40 gained 1.3%. EU equities are now up nearly 7% since January. The euro, meanwhile, gained 0.1% to trade around €1.17 against the dollar. The single currency has surged 13% against the greenback since the start of the year, as investors have sought to diversify from dollar-denominated assets to hedge against continuing US policy uncertainty. EU government borrowing costs remained broadly stable, with yields on German 10-year bonds – the eurozone benchmark – down 1 basis point (0.01 percentage point) to 2.63%. 'IT'S MIDNIGHT!!! BILLIONS OF DOLLARS IN TARIFFS ARE NOW FLOWING INTO THE UNITED STATES OF AMERICA!' US President Donald Trump wrote on his social media platform, Truth Social, earlier this morning. Trump's punishing levies, which purport to match the trade barriers imposed by US trading partners, are on average slightly lower than those introduced on 'Liberation Day' in early April, which upended the global economy before being suspended one week later. The strengthening euro and rising EU stocks come despite the fact that the new US duties on EU goods – agreed following a meeting between Trump and EU chief Ursula von der Leyen two weeks ago – are on average slightly higher than before. Trump had previously imposed a 50% tariff on steel and aluminium, a 25% duty on cars and car parts, and a 10% blanket levy on most other EU exports. The duties came on top of the 4.8% average rate on EU goods before Trump returned to the White House in January. Trump's 50% levies on steel and aluminium remain in force, although Brussels is still pushing for a 'quota system' in which some metal exports will be hit with a lower rate. The blanket 15% tariff does not currently apply to EU car exports, despite the fact that Washington and Brussels both say autos are covered by the flat levy. EU officials expect Trump to sign an executive duty lowering the auto tariff over the coming days. Products that are subject to a special 'Section 232' investigation, including pharmaceuticals and semiconductors, will continue to face the current 0% US import tax until the probes are completed. Trump suggested yesterday that semiconductor exports to the US would soon face a 100% duty. He also said earlier this week that pharma exports could eventually face tariffs as high as 250%. Washington and Brussels both say EU pharma and chip exports are covered by the 15% levy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store